Literature DB >> 14532921

[Classification of stomach adenocarcinomas].

Hernán Espejo Romero1, Jesús Navarrete Siancas.   

Abstract

Malignant stomach tumors include carcinomas, lymphomas, leimiosarcomas, carcinoids and other less frequent tumors. Adenocarcinoma has been classified in many different ways and by many different authors. Depending on its stage, early or advanced, on one side and according to the TNM staging system (Tumor, Nodes, Metastases) on the other. The early-stage adenocarcinoma, from the macroscopic point of view has been classified in I, IIa, IIc, IIb and III and combinations therefrom. Early-stage cancer has been denominated as O type and advanced cancer, which has been denominated by common practice, as Borrmann: I, II, III and IV, is now numbered using Arabic numbers 1, 2, 3 and 4. Type 5 is included, which would correspond to the non-classifiable carcinoma. Histologic classification according to Lauren, comprises intestinal, diffuse and the mixed or undifferentiated type which produces no mucus. According to Mulligan, it is classified as: pyloric glands and intestinal type cancer on one side and gastric type cell cancer on the other side. The WHO (World Health Organization) classifies them as: Papillary, tubular (tub.1, tub.2 and tub.3) signet ring cell, undifferentiated and mucinous adenocarcinoma. Nakamura, Kato and Hirota classify them as: differentiated and undifferentiated adenocarcinomas. Ming classifies them as: expanding type and infiltrating type. There is a tendency, when dealing with early-stage cancer, to group its forms in ulcerating carcinomas, vegetating carcinomas, localized gastritis-like and advanced-like carcinomas. The gastritis-like classification would correspond to form IIb of the initial classification of early-stage cancer. Broders' classification of Adenocarcinoma grade 1, 2, 3 and 4 is mentioned here as a classification solely on basis of the cellular differentiation. As historical classification, we include that of James Ewing. The above mentioned classifications relate to each other and are not excluding from the conceptual point of view.

Entities:  

Mesh:

Year:  2003        PMID: 14532921

Source DB:  PubMed          Journal:  Rev Gastroenterol Peru        ISSN: 1022-5129


  6 in total

Review 1.  The potential role of leptin in tumor invasion and metastasis.

Authors:  Amitabha Ray; Margot P Cleary
Journal:  Cytokine Growth Factor Rev       Date:  2017-11-11       Impact factor: 7.638

2.  Reverse Correlation between MicroRNA-145 and FSCN1 Affecting Gastric Cancer Migration and Invasion.

Authors:  Jia-jia Chen; Wang-yu Cai; Xue-wen Liu; Qi-cong Luo; Gang Chen; Wei-feng Huang; Na Li; Jian-chun Cai
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

3.  Primary gastric natural killer/T-cell lymphoma with diffuse CD30 expression and without CD56 expression: A case report.

Authors:  Lizhi Zhang; Pengxin Zhang; Jinhui Wen; Xuehua Chen; Hua Zhang
Journal:  Oncol Lett       Date:  2015-12-09       Impact factor: 2.967

4.  Prognostic impact of Ki-67 in patients with gastric cancer-the importance of depth of invasion and histologic differentiation.

Authors:  Gyung Hyuck Ko; Se-Il Go; Won Sup Lee; Jeong-Hee Lee; Sang-Ho Jeong; Young-Joon Lee; Soon Chan Hong; Woo Song Ha
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

5.  Copy number alterations and epithelial‑mesenchymal transition genes in diffuse and intestinal gastric cancers in Mexican patients.

Authors:  Violeta Larios-Serrato; José-Darío Martínez-Ezquerro; Hilda-Alicia Valdez-Salazar; Javier Torres; Margarita Camorlinga-Ponce; Patricia Piña-Sánchez; Martha-Eugenia Ruiz-Tachiquín
Journal:  Mol Med Rep       Date:  2022-04-01       Impact factor: 2.952

6.  Conversion therapy for advanced gastric cancer with trastuzumab combined with chemotherapy: A case report.

Authors:  Shuo-Meng Xiao; Rui Xu; Xiao-Li Tang; Zhi Ding; Ji-Man Li; Xiang Zhou
Journal:  Oncol Lett       Date:  2018-06-11       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.